X

Trial Profile

A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epacadostat (Primary) ; Cancer vaccine; Cancer vaccine
Indications Malignant melanoma
Focus Pharmacodynamics

Most Recent Events

05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
08 May 2018 Status changed from active, no longer recruiting to completed.
25 Apr 2018 According to an Incyte Corporation media release, data from this trial will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com